HomeInsightsStock Comparison

Divis Laboratories Ltd vs Lyka Labs Ltd Stock Comparison

Divis Laboratories Ltd vs Lyka Labs Ltd Stock Comparison

Last Updated on: May 10, 2025

Key Highlights

  • The Latest Trading Price of Divis Laboratories Ltd is ₹ 6001 as of 09 May 15:30.
  • The P/E Ratio of Divis Laboratories Ltd changed from 38.3 on March 2020 to 56.9 on March 2024 . This represents a CAGR of 8.24% over 5 yearsThe P/E Ratio of Lyka Labs Ltd changed from 10 on March 2022 to 0 on March 2024 . This represents a CAGR of -100.00% over 3 years.
  • The Market Cap of Divis Laboratories Ltd changed from ₹ 52763 crore on March 2020 to ₹ 91234 crore on March 2024 . This represents a CAGR of 11.57% over 5 yearsThe Market Cap of Lyka Labs Ltd changed from ₹ 36.58 crore on March 2020 to ₹ 350.59 crore on March 2024 . This represents a CAGR of 57.15% over 5 years.
  • The revenue of Divis Laboratories Ltd for the Dec '24 is ₹ 2401 crore as compare to the Sep '24 revenue of ₹ 2444 crore. This represent the decline of -1.76% The revenue of Lyka Labs Ltd for the Dec '24 is ₹ 34.62 crore as compare to the Sep '24 revenue of ₹ 41.18 crore. This represent the decline of -15.93%.
  • The ebitda of Divis Laboratories Ltd for the Dec '24 is ₹ 825 crore as compare to the Sep '24 ebitda of ₹ 822 crore. This represent the growth of 0.36% The ebitda of Lyka Labs Ltd for the Dec '24 is ₹ 6.02 crore as compare to the Sep '24 ebitda of ₹ 4.98 crore. This represent the growth of 20.88%.
  • The net profit of Divis Laboratories Ltd changed from ₹ 356 crore to ₹ 589 crore over 7 quarters. This represents a CAGR of 33.34% The net profit of Lyka Labs Ltd changed from ₹ -1.85 crore to ₹ 2.71 crore over 7 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Divis Laboratories Ltd changed from 33.04 % on March 2020 to 50.44 % on March 2024 . This represents a CAGR of 8.83% over 5 yearsThe Dividend Payout of Lyka Labs Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Divis Laboratories Ltd

  • Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
  • The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
  • It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
  • In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
  • It is among the largest pharmaceutical companies in India with a portfolio of approx.

About Lyka Labs Ltd

  • Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83.
  • It also added a range of ayurvedic and animal health care products over the years.
  • In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan.
  • Lyka Exports is the subsidiary of the company.
  • The Company is engaged in the business of pharmaceutical and related activities, including research. The company offers a broad range of antibiotics used as life-savers and to treat minor infections.

Divis Laboratories Ltd News Hub

News

Divis Laboratories to conduct board meeting

Divis Laboratories will hold a meeting of the Board of Directors of the Company on 17 May ...

Read more

08 May 2025 15:24

News

Divis Lab spurts as broker maintains buy call

In its latest note, the broker highlighted Divi's strong potential to emerge as a primary ...

Read more

24 Apr 2025 13:45

News

Divis Labs jumps on signing long-term manufacturing pact with global pharma major

In a regulatory filing on 18 April 2025, Divi's stated that the agreement pertains to the ...

Read more

21 Apr 2025 10:18

News

Divis Laboratories enters into long term manufacturing and supply agreement

Divis Laboratories has signed a long term manufacturing and supply agreement with a global...

Read more

18 Apr 2025 10:02

News

Divi's Laboratories announces change in senior management

Divi's Laboratories announced that G. Bala Kishore, serving as General Manager (EHS) of th...

Read more

31 Mar 2025 10:14

News

Volumes jump at Divis Laboratories Ltd counter

IndusInd Bank Ltd, Axis Bank Ltd, Gujarat State Petronet Ltd, Kaynes Technology India Ltd ...

Read more

12 Mar 2025 11:00

Lyka Labs Ltd News Hub

News

Lyka Labs EGM scheduled

Lyka Labs announced that an Extra Ordinary General Meeting (EGM) of the Company will be he...

Read more

01 Feb 2025 13:50

News

Lyka Labs announces board meeting date

Lyka Labs will hold a meeting of the Board of Directors of the Company on 4 February 2025....

Read more

03 Jan 2025 09:46

News

Lyka Labs to declare Quarterly Result

Lyka Labs will hold a meeting of the Board of Directors of the Company on 4 February 2025....

Read more

30 Dec 2024 18:47

News

Lyka Labs announces board meeting date

Lyka Labs will hold a meeting of the Board of Directors of the Company on 12 November 2024...

Read more

23 Oct 2024 10:45

News

Lyka Labs to hold board meeting

Lyka Labs will hold a meeting of the Board of Directors of the Company on 11 October 2024 ...

Read more

04 Oct 2024 16:39

News

Lyka Labs to hold board meeting

Lyka Labs will hold a meeting of the Board of Directors of the Company on 9 August 2024. P...

Read more

02 Aug 2024 11:26

SWOT Analysis Of Divis Laboratories Ltd

Strength

4

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Lyka Labs Ltd

Strength

1

S

Weakness

4

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Divis Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Lyka Labs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Divis Laboratories Ltd and Lyka Labs Ltd

Which company has a larger market capitalization, Divis Laboratories Ltd or Lyka Labs Ltd?

Market cap of Divis Laboratories Ltd is 159,310 Cr while Market cap of Lyka Labs Ltd is 382 Cr

What are the key factors driving the stock performance of Divis Laboratories Ltd and Lyka Labs Ltd?

The stock performance of Divis Laboratories Ltd and Lyka Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Divis Laboratories Ltd and Lyka Labs Ltd?

As of May 10, 2025, the Divis Laboratories Ltd stock price is INR ₹6001.1. On the other hand, Lyka Labs Ltd stock price is INR ₹107.1.

How do dividend payouts of Divis Laboratories Ltd and Lyka Labs Ltd compare?

To compare the dividend payouts of Divis Laboratories Ltd and Lyka Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions